Restricted accessResearch articleFirst published online 2006-8
Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD)
AliR.ThomasP.WhiteJ.McGregorC.DanzC.GowingL., (2003). Antagonistprecipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. Drug and Alcohol Review, 22, 425–431
2.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3.
BellJ.MattickR.HayA.ChanJ.HallW. (1997). Methadone maintenance and drugrelated crime. Journal of Substance Abuse, 9, 15–25
4.
BellJ.R.YoungM.R.MastermanS.C.MorrisA.MattickR.P.BammerG. (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. Medical Journal of Australia, 171, 26–30
5.
ChilversM.WeatherburnD. (2003). The impact of heroin dependence on long-term robbery trends. Crime and Justice Bulletin, no. 79, 1–12. NSW Bureau of Crime Statistics and Research, Sydney
6.
ClarkN.LintzerisN.GijsbersA.WhelanG.DunlopA.RitterA., (2002). LAAM maintenance vs methadone maintenance for heroin dependence. The Cochrane Database of Systematic Reviews, Issue 2. Oxford: Update Software.
7.
DaleyM.ArgeriouM.McCartyD.CallahanJ.J.Jr.ShepardD.S.WilliamsC.N. (2000). The costs of crime and the benefits of substance abuse treatment for pregnant women. Journal of Substance Abuse Treatment, 19, 445–458
8.
DarkeS. (1992). The measurement of outcome in opiate treatment evaluation studies. Drug and Alcohol Review, 11, 169–174
9.
DarkeS. (1998). Self-report among injecting drug users: A review. Drug and Alcohol Dependence, 51, 253–263
10.
DarkeS.HallW.SwiftW. (1994). Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. Drug and Alcohol Dependence, 34, 253–257
11.
DigiustoE.LintzerisN.BreenC.KimberJ.MattickR.P.BellJ., (2004). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD project. Addictive Behaviors, 30, 443–456
12.
DigiustoE.ShakeshaftA.RitterA.O'BrienS.MattickR.P. & the NEPOD Research Group (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction, 99, 450–460
13.
DigiustoE.MattickR.P.KimberJ.O'BrienS.DoranC.HendersonN., (2001). National Evaluation of Pharmacotherapies for Opioid Dependence — Why have we done it?Drug and Alcohol Review, 20, 139–141
14.
DonnellyN.WeatherburnD.ChilversM. (2004). The impact of the Australian heroin shortage on robbery in NSW. Crime and Justice Statistics Bureau Brief, March, 1–9. NSW Bureau of Crime Statistics and Research, Sydney.
15.
DoranC.M.ShanahanM.MattickR.P.AliR.WhiteJ.BellJ. (2003). Buprenorphine versus methadone maintenance: A cost-effectiveness analysis. Drug and Alcohol Dependence, 71, 295–302
16.
DoreG.M.WalkerJ.D.PaiceJ.R.ClarksonS. (1999). Methadone maintenance treatment: Outcomes from the Otago methadone programme. New Zealand Medical Journal, 112(1), 442–445
17.
FaggianoF.Vigna-TagliantiF.VersinoE.LemmaP. (2003). Methadone maintenance at different dosages for opioid dependence. The Cochrane Database of Systematic Reviews, Issue 3. Oxford: Update Software.
18.
FlynnP.M.KristiansenP.L.PortoJ.V.HubbardR.L. (1999). Costs and benefits of treatment for cocaine addiction in DATOS. Drug and Alcohol Dependence, 57, 167–174
19.
FreemanK. (2003). Health and well-being outcomes for drug-dependent offenders on the NSW drug court programme. Drug and Alcohol Review, 22, 409–416
20.
GibsonA.E.DoranC.M.BellJ.R.RyanA.LintzerisN. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial. Medical Journal of Australia, 179, 38–42
21.
GlasgowN.J.TaylorJ.BellJ.R.YoungM.R.BammerG. (2001). Accelerated withdrawal from methadone maintenance therapy using naltrexone and minimal sedation: A case series analysis. Drug and Alcohol Review, 20, 213–221
22.
GossopM.MarsdenJ.StewartD.RolfeA. (2000). Reductions in acquisitive crime and drug use after treatment of addiction problems: 1-year follow-up outcomes. Drug and Alcohol Dependence, 58, 165–172
23.
HallW.BellJ.CarlessJ. (1993). Crime and drug use among applicants for methadone maintenance. Drug and Alcohol Dependence, 31, 123–129
24.
A.KnappM.MarsdenJ.GossopM.StewartD. (2003). Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: Evidence from a national prospective cohort study. Journal of Health Service & Research Policy, 8, 134–141
25.
HutchinsonS.J.TaylorA.GruerL.BarrC.MillsC.ElliottL., (2000). One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction, 95, 1055–1068
26.
KayeS.DarkeS.Finlay-JonesR. (1998). The onset of heroin use and criminal behaviour: Does order make a difference?Drug and Alcohol Dependence, 53(1), 79–86
27.
KirchmayerU.DavoliM.VersterA. (2003). Naltrexone maintenance treatment for opioid dependence. The Cochrane Database of Systematic Reviews, Issue 2. Oxford: Update Software.
28.
KoenigL.SiegelJ.M.HarwoodH.GilaniJ.ChenY.J.LeahyP., (2005). Economic benefits of substance abuse treatment: Findings from Cuyahoga County, Ohio. Journal of Substance Abuse Treatment, 28, S41–S50
29.
LawM.G.LynskeyM.RossJ.HallW.Back-projection estimates of the number of dependent heroin users in Australia. Addiction, 96, 433–443
30.
LawrenceR.FreemanK. (2002). Design and implementation of Australia's first drug court. The Australian and New Zealand Journal of Criminology, 35, 63–78
31.
LindB.ChenS.WeatherburnD.MattickR. (2004). The effectiveness of methadone maintenance treatment in controlling crime: An aggregate level analysis. Crime and Justice Statistics Bureau Brief, March, 1–9. NSW Bureau of Crime Statistics and Research, Sydney.
32.
LintzerisN.RitterA.PanjariM.ClarkN.KutinJ.BammerG. (2004). Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. The American Journal on Addictions, 13, S29–S41
33.
MaherL.DixonD.HallW.LynskeyM. (2002). Property crime and income generation by heroin users. Australian and New Zealand Journal of Criminology, 35, 187–202
34.
MakkaiT.FitzgeraldJ.DoakP. (2000). Drug use among police detainees. Crime and Justice Bulletin, 49, 1–8. Sydney: N.S.W. Bureau of Crime Statistics and Research.
35.
MarschL.A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior & criminality: A meta-analysis. Addiction, 93, 515–532
36.
MattickR.P.AliR.WhiteJ.M.O'BrienS.WolkS.DanzC. (2003). Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98, 441–452
37.
MattickR.P.BreenC.KimberJ.DavoliM. (2003). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews, Issue 2. Oxford: Update Software.
38.
MattickR.P.KimberJ.BreenC.DavoliM. (2003). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, Issue 3. Oxford: Update Software.
39.
McGregorC.AliR.WhiteJ.M.ThomasP.GowingL. (2002). A comparison of antagonist- precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: Outcomes at 6 and 12 months. Drug and Alcohol Dependence, 68, 5–14
40.
PaniP.P.MaremmaniI.PirastuR.TagliamonteA.GessaG.L. (2000). Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence, 60, 39–50
41.
RajkumarA.S.FrenchM.T. (1997). Drug abuse, crime costs, and the economic benefits of treatment. Journal of Quantitative Criminology, 13, 291–323
42.
ReaF.BellJ.R.YoungM.R.MattickR.P. (2004). A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug and Alcohol Dependence, 75, 79–88
43.
RitterA.J. (2002). Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose. Australian and New Zealand Journal of Psychiatry, 36, 224–228
44.
RitterA.J.LintzerisN.ClarkN.KutinJ.BammerG.PanjariM. (2003). A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction, 98, 1605–1613
45.
RosenheckR.KostenT. (2001). Buprenorphine for opiate addiction: Potential economic impact. Drug and Alcohol Dependence, 63, 253–262
46.
RothbardA.AltermanA.RutherfordM.LiuF.ZelinskiS.McKayJ. (1999). Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. Journal of Substance Abuse Treatment, 16, 329–335
47.
ShanahanM.D.DoranC.M.DigiustoE.BellJ.LintzerisN.WhiteJ., (2006). A costeffectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviors, 31, 371–387
48.
ShanahanM.LancsarE.HaasM.LindB.WeatherburnD.ChenS. (2004). Cost-effectiveness analysis of the New South Wales adult drug court program. Evaluation Review, 28, 3–27
49.
SheerinI.GreenT.SellmanD.AdamsonS.DeeringD. (2004). Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand. The New Zealand Medical Journal, 117(1190).
50.
SiegelS.Jr.CastellanN.J. (1988). Nonparametric statistics for the behavioral sciences2nd ed.New York: McGraw Hill.
51.
StenbackaM.LeifmanA.RomelsjoA. (2003). The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods. Drug and Alcohol Review, 22, 27–34
52.
ToppL.DarkeS.BrunoR.FryC.HargreavesK.HumeniukR., (2001). Findings of the Illicit Drug Reporting System (IDRS) (NDARC Monograph Number 47). Sydney: National Drug and Alcohol Research Centre.
53.
WeatherburnD.LindB. (1999). Heroin harm minimization: Do we really have to choose between law enforcement and treatment?. Crime and Justice Bulletin, 46, 1–11
54.
WilkinsC.BhattaK.CasswellS. (2002). The emergence of amphetamine use in New Zealand: Findings from the 1998 and 2001 National Drug Surveys. The New Zealand Medical Journal, 115, 1166